| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
|
J Clin Oncol
|
2007
|
3.91
|
|
2
|
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
|
J Clin Oncol
|
2010
|
2.43
|
|
3
|
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
|
J Clin Oncol
|
2005
|
1.99
|
|
4
|
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
|
Clin Cancer Res
|
2012
|
1.64
|
|
5
|
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
1.56
|
|
6
|
Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain.
|
Dis Colon Rectum
|
2003
|
1.51
|
|
7
|
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
|
J Clin Oncol
|
2004
|
1.44
|
|
8
|
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
|
J Clin Oncol
|
2007
|
1.14
|
|
9
|
Tumor angiogenesis and novel antiangiogenic strategies.
|
Int J Cancer
|
2010
|
1.08
|
|
10
|
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
0.96
|
|
11
|
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
|
Clin Cancer Res
|
2013
|
0.91
|
|
12
|
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
|
Clin Cancer Res
|
2010
|
0.91
|
|
13
|
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
|
Clin Cancer Res
|
2011
|
0.80
|
|
14
|
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.
|
Invest New Drugs
|
2009
|
0.78
|
|
15
|
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
|
Clin Cancer Res
|
2006
|
0.77
|
|
16
|
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.77
|
|
17
|
False-positive splenic imaging secondary to cavernous transformation of the portal venous system in non-Hodgkin's lymphoma.
|
Clin Nucl Med
|
2003
|
0.75
|
|
18
|
AIRP best cases in radiologic-pathologic correlation: cardiac echinococcus infection.
|
Radiographics
|
2013
|
0.75
|
|
19
|
CT- and computer-based features of small hamartomas.
|
Clin Imaging
|
2011
|
0.75
|
|
20
|
High resolution computed tomography in idiopathic interstitial pneumonias.
|
Mt Sinai J Med
|
2009
|
0.75
|
|
21
|
Imaging of coronary artery calcification.
|
Mt Sinai J Med
|
2002
|
0.75
|